LQDALiquidia Corporation
Price
+21%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growth steady, the market undecided.
We are a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases such as pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease (“PH-ILD”). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC, formerly known as RareGen.
In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Liquidia Corporation (LQDA) reported revenue of $172M in Q2 2026 (quarter ended Jun 30, 2026), up 1843% from the same quarter a year earlier. That came with net income of $75M (44% of revenue). For the full year FY2025, revenue was $158M (+1031% year on year) and net income −$69M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026On September 30, 2026, Liquidia Corporation, a Delaware corporation (the “Company”), issued a press release regarding the litigation filed by United Therapeutics Corporation in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 and the Company’s lead …Other event · Form 8-K
- Sep 3, 2026On September 3, 2026, Liquidia Corporation, a Delaware corporation (the “Company”), issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to YUTREPIA ® (treprostinil) inhalation powder for the treatment of Raynaud’s phenomenon associated with systemic sclerosis.Other event · Form 8-K
- Aug 12, 2026On August 12, 2026, the Company updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #30 of 41 by RyuScore